Cargando…

Assessing Visual Outcomes: A Comparative Study of US-FDA Premarket Approval Data for Multifocal and EDOF Lens Implants in Cataract Surgery

This study compares the efficacy, safety, and patient-reported outcomes of three intraocular implants (IOL): Tecnis Synergy IOL, AcrySof IQ PanOptix Trifocal, and Tecnis Symfony EDOF IOL. Participants achieving 20/20 or better uncorrected binocular visual acuity were as follows: Synergy—67% distance...

Descripción completa

Detalles Bibliográficos
Autores principales: Moshirfar, Majid, Stoakes, Isabella M., Theis, Joshua S., Porter, Kaiden B., Santos, Jordan M., Martheswaran, Tanisha, Payne, Carter J., Hoopes, Phillip C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342887/
https://www.ncbi.nlm.nih.gov/pubmed/37445400
http://dx.doi.org/10.3390/jcm12134365
_version_ 1785072606692507648
author Moshirfar, Majid
Stoakes, Isabella M.
Theis, Joshua S.
Porter, Kaiden B.
Santos, Jordan M.
Martheswaran, Tanisha
Payne, Carter J.
Hoopes, Phillip C.
author_facet Moshirfar, Majid
Stoakes, Isabella M.
Theis, Joshua S.
Porter, Kaiden B.
Santos, Jordan M.
Martheswaran, Tanisha
Payne, Carter J.
Hoopes, Phillip C.
author_sort Moshirfar, Majid
collection PubMed
description This study compares the efficacy, safety, and patient-reported outcomes of three intraocular implants (IOL): Tecnis Synergy IOL, AcrySof IQ PanOptix Trifocal, and Tecnis Symfony EDOF IOL. Participants achieving 20/20 or better uncorrected binocular visual acuity were as follows: Synergy—67% distance, 64% intermediate, and 47% near; PanOptix—73% distance, 73% intermediate, and 50% near; and Symfony—63% distance, 75% intermediate, and 22% near. Symfony demonstrated superior intermediate visual acuity compared to Synergy (p = 0.0182) for those achieving 20/25 or better. Both Synergy and PanOptix showed superiority over Symfony for near visual acuity (p < 0.0001). Halos were statistically more common in Synergy participants compared to PanOptix (p = 0.0013) and Symfony (p < 0.0001). Each trial lens outperformed its monofocal IOL in terms of independence from glasses or contacts, with Synergy and PanOptix showing statistical significance over Symfony. Comparing contrast sensitivities and defocus curves was challenging due to data variance and as such, standardization of United States Food and Drug Administration (US-FDA) data reporting is key for better comparison of outcomes among different IOL platforms.
format Online
Article
Text
id pubmed-10342887
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103428872023-07-14 Assessing Visual Outcomes: A Comparative Study of US-FDA Premarket Approval Data for Multifocal and EDOF Lens Implants in Cataract Surgery Moshirfar, Majid Stoakes, Isabella M. Theis, Joshua S. Porter, Kaiden B. Santos, Jordan M. Martheswaran, Tanisha Payne, Carter J. Hoopes, Phillip C. J Clin Med Article This study compares the efficacy, safety, and patient-reported outcomes of three intraocular implants (IOL): Tecnis Synergy IOL, AcrySof IQ PanOptix Trifocal, and Tecnis Symfony EDOF IOL. Participants achieving 20/20 or better uncorrected binocular visual acuity were as follows: Synergy—67% distance, 64% intermediate, and 47% near; PanOptix—73% distance, 73% intermediate, and 50% near; and Symfony—63% distance, 75% intermediate, and 22% near. Symfony demonstrated superior intermediate visual acuity compared to Synergy (p = 0.0182) for those achieving 20/25 or better. Both Synergy and PanOptix showed superiority over Symfony for near visual acuity (p < 0.0001). Halos were statistically more common in Synergy participants compared to PanOptix (p = 0.0013) and Symfony (p < 0.0001). Each trial lens outperformed its monofocal IOL in terms of independence from glasses or contacts, with Synergy and PanOptix showing statistical significance over Symfony. Comparing contrast sensitivities and defocus curves was challenging due to data variance and as such, standardization of United States Food and Drug Administration (US-FDA) data reporting is key for better comparison of outcomes among different IOL platforms. MDPI 2023-06-28 /pmc/articles/PMC10342887/ /pubmed/37445400 http://dx.doi.org/10.3390/jcm12134365 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Moshirfar, Majid
Stoakes, Isabella M.
Theis, Joshua S.
Porter, Kaiden B.
Santos, Jordan M.
Martheswaran, Tanisha
Payne, Carter J.
Hoopes, Phillip C.
Assessing Visual Outcomes: A Comparative Study of US-FDA Premarket Approval Data for Multifocal and EDOF Lens Implants in Cataract Surgery
title Assessing Visual Outcomes: A Comparative Study of US-FDA Premarket Approval Data for Multifocal and EDOF Lens Implants in Cataract Surgery
title_full Assessing Visual Outcomes: A Comparative Study of US-FDA Premarket Approval Data for Multifocal and EDOF Lens Implants in Cataract Surgery
title_fullStr Assessing Visual Outcomes: A Comparative Study of US-FDA Premarket Approval Data for Multifocal and EDOF Lens Implants in Cataract Surgery
title_full_unstemmed Assessing Visual Outcomes: A Comparative Study of US-FDA Premarket Approval Data for Multifocal and EDOF Lens Implants in Cataract Surgery
title_short Assessing Visual Outcomes: A Comparative Study of US-FDA Premarket Approval Data for Multifocal and EDOF Lens Implants in Cataract Surgery
title_sort assessing visual outcomes: a comparative study of us-fda premarket approval data for multifocal and edof lens implants in cataract surgery
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342887/
https://www.ncbi.nlm.nih.gov/pubmed/37445400
http://dx.doi.org/10.3390/jcm12134365
work_keys_str_mv AT moshirfarmajid assessingvisualoutcomesacomparativestudyofusfdapremarketapprovaldataformultifocalandedoflensimplantsincataractsurgery
AT stoakesisabellam assessingvisualoutcomesacomparativestudyofusfdapremarketapprovaldataformultifocalandedoflensimplantsincataractsurgery
AT theisjoshuas assessingvisualoutcomesacomparativestudyofusfdapremarketapprovaldataformultifocalandedoflensimplantsincataractsurgery
AT porterkaidenb assessingvisualoutcomesacomparativestudyofusfdapremarketapprovaldataformultifocalandedoflensimplantsincataractsurgery
AT santosjordanm assessingvisualoutcomesacomparativestudyofusfdapremarketapprovaldataformultifocalandedoflensimplantsincataractsurgery
AT martheswarantanisha assessingvisualoutcomesacomparativestudyofusfdapremarketapprovaldataformultifocalandedoflensimplantsincataractsurgery
AT paynecarterj assessingvisualoutcomesacomparativestudyofusfdapremarketapprovaldataformultifocalandedoflensimplantsincataractsurgery
AT hoopesphillipc assessingvisualoutcomesacomparativestudyofusfdapremarketapprovaldataformultifocalandedoflensimplantsincataractsurgery